Bionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Bionano Genomics (BNGO) will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A pre-recorded presentation will be accessible on the Company’s Investor Resources page on September 12 at 7:00 am ET. Bionano Genomics focuses on genome analysis solutions, providing optical genome mapping technologies and diagnostic services, including testing for autism spectrum disorder and other neurodevelopmental disabilities. The Company aims to transform genomic research through advanced software and services.

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24^th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded presentation will be available on the Investor Resources page of the Company's website on Monday, September 12 at 7:00 am ET.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com

CONTACTS

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com

FAQ

When is Bionano Genomics participating in the H.C. Wainwright Annual Conference?

Bionano Genomics will participate from September 12-14, 2022.

What will Bionano Genomics present at the conference?

A pre-recorded presentation will be available on their Investor Resources page on September 12 at 7:00 am ET.

What is the focus of Bionano Genomics?

Bionano Genomics specializes in genome analysis solutions and optical genome mapping.

What diagnostic services does Bionano Genomics offer?

The Company offers diagnostic testing for autism spectrum disorder and neurodevelopmental disabilities.

How can I learn more about Bionano Genomics?

For more information, visit the official websites of Bionano Genomics, Lineagen, and BioDiscovery.